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Introduction
Previously, we investigated the maximum tolerated dose and dose-limiting toxicity in 3 phase 1 trials involving a total of 123 patients with hematopoietic malignancies and various solid tumors [1] - [3] . Based on our findings, it was decided to recommend a dosing schedule in which 1.3 mg/m 2 of bortezomib (Bor) is administered twice a week for 2 weeks, followed by a 10-day washout period. Bor at 1.3 mg/m 2 is also usually given for multiple myeloma via subcutaneous injections administered once or twice weekly. Although several trials involving increased amounts of Bor have been conducted [4] - [6] , there have been no reports of long-term, once-monthly 1.3 mg/m 2 of Bor administration as maintenance therapy. Moreover, we could find no examples in the literature that evaluated the efficacy and safety of increasing the Bor dose to 1.6 mg/m 2 in such patients. Moreover, to date there have been no reports in which subcutaneous Bor injections were administered at a once-monthly dosage of 1.6 mg/m 2 . Bor therapy, which can offer equivalent therapeutic efficacy while reducing the adverse event frequency, is administered by a subcutaneous injection from an intravenous infusion; non-inferiority studies of subcutaneous Bor injections also exist [7] . However, the blood concentration of Bor at the time of subcutaneous administration is known to have a lower peak value than that during intravenous administration [8] [9] ; considering the fact that a larger dosage may be more appropriate when subcutaneously injecting Bor roughly once monthly as maintenance therapy, we conducted this clinical trial to investigate the optimum Bor dosage for maintenance therapy.
Materials and Methods
This clinical trial was a single-center, non-randomized, prospective study. The main endpoint was safety and the secondary endpoint was therapeutic efficacy. Twenty-two patients with multiple myeloma who were already receiving BD 1.3 mg/m 2 therapy were administered BD 1.6 mg/m 2 therapy ( Table 1) . Of the 22 patients, 13 had IgG-, 2 had IgA-type, and 7 had Bence-Jones protein (BJP)-type multiple myeloma. The median age was 68.5 years (range: 44 -90 years). The period during which Bor was administered at 1.3 mg/m 2 at least once monthly as a pretreatment ranged from 8 to 52 months, with a median of 26.5 months. In all therapeutic approaches, Dex was administered at 20 mg/body on the same day as and the day after Bor administration. Psl, which is used in bone morphogenetic protein (BMP) therapy, was administered at 20 mg/day for roughly 4 days per month; however, appropriate increases or decreases were made at the attending physician's discretion. Tha was administered every day at 50 or 100 mg/body without a washout period. Len was administered every day for 28 days at 10 or 15 mg/body. The therapeutic effect of increasing the Bor dose was only investigated in IgG-and IgA-type patients, and the evaluation period was the entire period during which the Bor dose was increased. Tha was later added to the regimens of 2 patients who underwent BMP therapy and 7 patients who underwent bortezomib and dexamethasone (BD) therapy; however, because 1 patient in the BMP therapy group and 4 patients in the BD therapy group had IgG-or IgA-type multiple myeloma, they were also subject to therapeutic evaluation.
Meanwhile, the safety of Bor-increase therapy was evaluated throughout the entire period, during which subcutaneous injections of Bor were administered once monthly at a dose of 1.6 mg/m 2 to all IgG-, IgA-, and BJPtype patients. The observation period ranged from 28 to 435 days, with a median of 400 days.
The clinical research ethics committee of the institution with which the authors are affiliated approved this study following review (review reference number 431, clinical trial registration number 431). All patients received advance explanations of the purpose of this study and gave their written consent to participate.
Prophylactic Administration of Antibiotics
No acyclovir, sulfamethoxazole/trimetoprim combinations, or other antibiotics were administered. 
Determining Therapeutic Efficacy
Judgments were made based on the criteria of the International Myeloma Working Group (IMWG).
Results
The therapeutic efficacy was determined for a total of 15 patients with IgG-and IgA-type multiple myeloma. The observation period ranged from 84 to 421 days, with a median of 400 days. No patients achieved complete remission (CR), very good partial remission (VGPR), or partial remission (PR) with increased Bor doses alone; 10 patients had a stable disease (SD) and 5 had a progressive disease (PD; Table 3 ). Nine patients subsequently changed to BDT50 therapy, and the therapeutic efficacy was determined for 5 of these patients (numbers 1, 7, 8, 11, and 12). Of these, 2 patients achieved PR (patient numbers 8 and 11), and the remaining patients had SD (2 patients; numbers 7 and 12) or PD (1 patient; number 1). Meanwhile, adverse events were evaluated in all patients, including those with BJP-type multiple myeloma. This observation period ranged from 28 to 435 days, with a median of 400 days. Grades 3 and 4 hematological toxicity was observed for a total of 5 times in 3 patients, whereas Grades 3 and 4 non-hematological toxicity was observed for a total of 14 times in 12 of 22 patients ( Table 4) . No patients died. 8 of the 22 patients discontinued Bor at 1.6 mg/m 2 because of herpes zoster (1 patient; number 3), malaise (1 patient; number 6), interstitial pneumonia (1 patient; number 13), and PD (3 patients; numbers 14, 17, and 22). Patients 16 and 18 were aged 87 and 85 years, respectively, and given the frequency of adverse events, they discontinued Bor at 1.6 mg/m 2 owing to old age at the discretion of their attending physician.
Discussion
Although there are only a few existing reports of Bor administration at doses 1.3 mg/m 2 or higher [4] - [6] , it was typical in earlier reports to administer Bor once weekly. We found no reports that directly compared Bor doses of 1.3 mg/m 2 and 1.6 mg/m 2 , and few reports investigated the boosting effect of increasing the Bor dose in patients receiving long-term1.3 mg/m 2 Bor therapy or once-monthly Bor administrations as maintenance therapy. In actual clinical settings, frequent outpatient clinic visits by elderly patients incur significant costs for medical professionals, patients, and insurers, and future increases in the number of elderly individuals means that discussions regarding costs cannot be avoided. One vial of Bor currently contains 3 mg; however, the amount of wasted Bor is extremely large, given the Japanese physique. In fact, Bor was used a total of 2986 times at our hospital in the 1-year period beginning in July 2013, of which 2549 instances (approximately 85%) involved doses of less than 2.5 mg/body. In the present study, we investigated whether unnecessary waste could be reduced and illness could be improved by increasing the dosage of Bor per injection.
A higher frequency of infectious diseases, including herpes zoster, was observed compared to the past report patients' conditions were stable following low-frequency Bor injection-based therapy was above a median of 24.5 months (7 -49 months) when counted from the pretreatment phase, suggesting the presence of patients whose conditions could be controlled with once-monthly Bor (Velcade) administration. The statuses of the subjects in the present study suggest that at least once-monthly Bor injection could inhibit disease progression. In future, it will be necessary to clarify whether any patient's condition could be stabilized with low-frequency therapy. We also hope for a more detailed investigation of the optimum low-frequency Bor maintenance therapy.
